RESUMO
The capability of imidacloprid 10% + flumethrin 4.5% (Seresto®) collars to prevent transmission of Borrelia burgdorferi sensu lato (Bbsl) and Anaplasma phagocytophilum (Ap) by naturally infected ticks was evaluated in two studies with 44 dogs. In each study, one group served as non-treated control, whereas the other groups were treated with the Seresto® collar. All dogs were exposed to naturally Bbsl- and Ap-infected hard ticks (Ixodes ricinus, Ixodes scapularis). In study 1, tick infestation was performed on study day (SD) 63 (2 months post-treatment [p.t.]); in study 2, it was performed on SD 32 (one month p.t.) respectively SD 219 (seven months p.t.). In situ tick counts were performed 2 days after infestation. Tick counts and removals followed 6 (study 1) or 5 days (study 2) later. Blood sampling was performed for the detection of specific Bbsl and Ap antibodies and, in study 1, for the documentation of Ap DNA by PCR. Skin biopsies were examined for Bbsl by PCR and culture (only study 1). The efficacy against Ixodes spp. was 100% at all time points. In study 1, two of six non-treated dogs became infected with Bbsl, and four of six tested positive for Ap; none of the treated dogs tested positive for Bbsl or Ap. In study 2, ten of ten non-treated dogs became infected with Bbsl and Ap; none of the treated dogs tested positive for Bbsl or Ap; 100% acaricidal efficacy was shown in both studies. Transmission of Bbsl and Ap was successfully blocked for up to 7 months.
Assuntos
Acaricidas/uso terapêutico , Transmissão de Doença Infecciosa/veterinária , Doenças do Cão/tratamento farmacológico , Ehrlichiose/veterinária , Doença de Lyme/veterinária , Infestações por Carrapato/veterinária , Acaricidas/administração & dosagem , Anaplasma phagocytophilum/genética , Anaplasma phagocytophilum/imunologia , Anaplasma phagocytophilum/fisiologia , Animais , Anticorpos Antibacterianos/sangue , Vetores Aracnídeos/microbiologia , Borrelia burgdorferi/genética , Borrelia burgdorferi/imunologia , Borrelia burgdorferi/fisiologia , DNA Bacteriano/sangue , Transmissão de Doença Infecciosa/prevenção & controle , Doenças do Cão/prevenção & controle , Doenças do Cão/transmissão , Cães , Ehrlichiose/prevenção & controle , Ehrlichiose/transmissão , Ixodes/microbiologia , Doença de Lyme/prevenção & controle , Doença de Lyme/transmissão , Neonicotinoides/administração & dosagem , Nitrocompostos/administração & dosagem , Piretrinas/administração & dosagem , Infestações por Carrapato/tratamento farmacológico , Infestações por Carrapato/microbiologia , Infestações por Carrapato/parasitologia , Resultado do TratamentoRESUMO
Crenosoma vulpis is a metastrongylid lungworm of canids causing chronic respiratory disease in dogs in parts of North America and Europe. The objective of this study was to determine the efficacy of imidacloprid 10% + moxidectin 2.5% (Advantage Multi/Advocate Topical Solution) against C. vulpis infection in experimentally infected dogs. Eighteen beagles (9 M, 9 F) were each given 100 infective third-stage larvae of C. vulpis. The 16 dogs (8 M, 8 F) with the highest faecal larval counts were stratified by gender and larval counts and randomly assigned to a treatment group. Group 1 received placebo only; group 2 was given a single topical treatment of Advantage Multi/Advocate (10 mg/kg imidacloprid/2.5 mg/kg moxidectin) at 4 weeks PI. Dogs were euthanised at 8 weeks PI and the lungs were removed and examined for the presence of adult worms by lung flush. The mean (geometric) number for adult C. vulpis recovered in untreated dogs was 70.0 (range 58 to 87) compared with 0.0 in animals treated with Advantage Multi/Advocate. The resulting efficacy against C. vulpis was 100%. The number of C. vulpis was significantly lower for treated dogs than the burden shown in the untreated group (p = 0.003).
Assuntos
Anti-Helmínticos/uso terapêutico , Doenças do Cão/tratamento farmacológico , Imidazóis/uso terapêutico , Nitrocompostos/uso terapêutico , Infecções por Strongylida/veterinária , Administração Tópica , Animais , Anti-Helmínticos/administração & dosagem , Doenças do Cão/parasitologia , Cães , Combinação de Medicamentos , Imidazóis/administração & dosagem , Pulmão/parasitologia , Macrolídeos/administração & dosagem , Macrolídeos/uso terapêutico , Metastrongyloidea/efeitos dos fármacos , Neonicotinoides , Nitrocompostos/administração & dosagem , Placebos/administração & dosagem , Soluções/uso terapêutico , Infecções por Strongylida/tratamento farmacológico , Infecções por Strongylida/parasitologia , Resultado do TratamentoRESUMO
The administration of three consecutive daily doses of the recommended 1x dose of Drontal Plus flavour tablets (Bayer) was examined for its effect on Giardia sp. cyst-shedding in 7 treated and 7 untreated random-source dogs. Dogs were treated on study days 0, 1 and 2. Cysts were quantified using direct immunofluorescent labelling on days -7, -5, -3 and -2, and daily from day 1 through 11. Three treated dogs never shed cysts again during the study, one shed again only on day 4, and the remaining three dogs started to shed again on days 8, 9 and 11. The mean numbers of cysts per gramme in the faeces of the treated dogs were significantly reduced (t-tests using log(10)(counts)) on days 1 and 2 (geometric means: controls = 447,000; treated = 1,050; p = 0.004) and days 3 to 8 (geometric means: controls = 23,400; treated 5.0; p < 0.001). Four controls that had been consistently positive, changed to negative status on day 11, and thus, on the final day of the trial, there were only three positive control and three positive treated dogs. Three consecutive days of treatment with Drontal Plus flavour tablets halted Giardia sp. cyst shedding by dogs. But starting six days post third treatment, some of the dogs started shedding cysts again. Since the prepatent period of Giardia sp. can be as short as 4 days, shedding of Giardia sp. cysts 6 days after treatment could be caused by a reinfection.
Assuntos
Antiprotozoários/uso terapêutico , Doenças do Cão/tratamento farmacológico , Giardia/efeitos dos fármacos , Giardíase/veterinária , Guanidinas/uso terapêutico , Praziquantel/uso terapêutico , Pamoato de Pirantel/uso terapêutico , Animais , Antiprotozoários/administração & dosagem , Doenças do Cão/parasitologia , Cães , Combinação de Medicamentos , Fezes/parasitologia , Giardíase/tratamento farmacológico , Guanidinas/administração & dosagem , Contagem de Ovos de Parasitas , Praziquantel/administração & dosagem , Pamoato de Pirantel/administração & dosagem , Comprimidos/administração & dosagem , Resultado do TratamentoRESUMO
This guideline is intended as an aid in the design, implementation and interpretation of studies for the assessment of drug efficacy against Eimeria in cattle and sheep, Cystoisospora in pigs and dogs, and Cryptosporidium in cattle. It deals with the most important aspects of how to conduct both experimental and field studies for dose determination, dose confirmation and assessment of field effectiveness. Also, guidance on the selection of animals, diagnostic techniques, statistical evaluation and methods for the preparation, maintenance and use of parasites is provided. The specific management conditions that may influence the course of natural infections and consequently determine treatment schemes are mentioned and suggestions for best practice in sampling and evaluation of data prior to conducting of efficacy studies are given. The guideline is also intended to assist investigators in carrying out specific studies, provide relevant information for registration authorities involved in the decision-making process, assist in the approval of anticoccidial drugs in the target species, and facilitate the world-wide adoption of standard procedures. Although currently not implemented, issues of drug resistance testing and alternative methods for drug testing are also discussed as future issues in drug testing against mammalian coccidia.
Assuntos
Coccídios/efeitos dos fármacos , Coccidiose/veterinária , Coccidiostáticos/uso terapêutico , Guias como Assunto , Animais , Bovinos , Coccidiose/tratamento farmacológico , Coccidiose/parasitologia , Cães , Avaliação de Medicamentos/veterinária , Ovinos , Suínos , Medicina VeterináriaRESUMO
Canine intestinal coccidiosis is a cause of diarrhea in young dogs and dogs that are immunocompromised. Reports in the literature indicate that experimental reproduction of clinical coccidiosis with Cystoisospora canis (syn. Isospora canis) is difficult, and few studies have been done with C. canis. Experimental oral infections were attempted in 22, 6- to 8-wk-old female beagles with 5 x 10(4) (n = 2) or 1 x 10(5) (n = 20) sporulated C. canis oocysts. Diarrhea was observed in all inoculated dogs. Diarrhea began 2-3 days before oocyst excretion. Five of the 22 dogs were given an anticoccidial (sulfadimethoxine) because of their clinical signs. The mean prepatent period was 9.8 days (range, 9-11 days, n = 22 dogs), and the patent period was 8.9 days (range, 7-18 days, n = 20 dogs). Two dogs exhibiting clinical coccidiosis were examined at necropsy 10 days after infection. Developmental stages of C. canis were present in cells in the lamina propria throughout the entire small intestine in both dogs. Microscopic lesions observed in both of these dogs were villous atrophy, dilation of lacteals, and hyperplasia of lymph nodes in Peyer's patches. Results of bacterial and viral examinations of these 2 dogs were negative, indicating that intestinal coccidiosis was the cause of the diarrhea. Our study indicates that C. canis can be a primary cause of diarrhea in young dogs.